幽门螺杆菌克拉霉素耐药的分子生物学检测研究进展

发布时间：2017-12-30 20:40

本文关键词：幽门螺杆菌克拉霉素耐药的分子生物学检测研究进展　出处：《中华医院感染学杂志》2017年05期 　论文类型：期刊论文

【摘要】：幽门螺杆菌(H.pylori)是慢性活动性胃炎、消化性溃疡、胃黏膜相关淋巴组织淋巴瘤和胃癌的主要致病因素;幽门螺杆菌根除治疗方案很多,其中铋剂+质子泵抑制剂+2种抗菌药物组成的四联疗法仍是当前国内外公认的一线治疗方法;由于H.pylori对多种抗菌药物耐药,使根除率有所下降,其中对克拉霉素耐药成为根除失败最主要的原因;从分子水平来研究H.pylori对克拉霉素的耐药性成为近年来广大胃肠病工作者研究的热点,分子生物学方法对克拉霉素耐药性的检测都是基于对H.pylori 23S rRNA基因突变的检测。因此,寻求一种简便、高效、经济、非侵入性的分子耐药性检测方法,对于选择个体化的幽门螺杆菌根除方案有着重要的临床意义。
[Abstract]:Helicobacter pylori (H.pylori) is a chronic active gastritis, peptic ulcer, the main pathogenesis of gastric mucosa associated lymphoid tissue lymphoma and gastric cancer treatment of many factors; the eradication of Helicobacter pylori, which consists of bismuth + proton pump inhibitor +2 antibiotics quadruple therapy is still at home and abroad as the first-line treatment due to antimicrobial; drug resistance of H.pylori, the eradication rate declined, the resistance to clarithromycin has become the main reason of the failure of eradication; from the molecular level to study the H.pylori resistance to clarithromycin has become the focus of the gastrointestinal disease researchers in recent years, the detection of clarithromycin resistance molecular biology methods are mutation detection on H.pylori 23S based on rRNA gene therefore, for a simple, efficient, economical, non-invasive detection method of molecular drug resistance, for the choice of individual The eradication scheme of Helicobacter pylori has important clinical significance.

【作者单位】：南通大学附属东台人民医院检验科;
【基金】：江苏省卫生计生委2015年度指导性科研基金资助项目(Z201527) 盐城市科技计划基金资助项目(YK2014088;YK2015086)
【分类号】：R440
【正文快照】： 幽门螺杆菌(H.pylori)是慢性胃炎和消化性溃疡的主要病因,与胃癌、胃黏膜相关淋巴组织(MALT)淋巴瘤及一些胃外疾病关系密切,已被世界卫生组织列入I类致癌原。随着抗菌药物在临床上广泛应用,H.pylori的耐药菌株也日益增加[1]。H.pylori对抗菌药物耐药是导致H.pylori根除率下降

【参考文献】